Nuzenio

After Casgevy Expansion

After Casgevy Expansion news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 5 latest news signals 5 publisher sources 100/100 entity strength

Latest news

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310 (NASDAQ:CRSP) - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 14:09:04 GMTWhy CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline Updates - And What's Next - simplywall.stsimplywall.st · Wed, 05 Aug 2026 04:44:10 GMTCrispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating - TipRanksTipRanks · Tue, 04 Aug 2026 15:51:47 GMTWorld's First Gene Therapy for 2-Year-Old Children | Root-Cause Intervention for Early Childhood Hematological Diseases - 36Kr36Kr · Fri, 31 Jul 2026 01:05:02 GMTMorgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? - The Globe and MailThe Globe and Mail · Thu, 30 Jul 2026 21:58:00 GMT

Timeline

Wed, 05 Aug 2026 14:09:04 GMTCRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310 (NASDAQ:CRSP) - Seeking Alpha
Wed, 05 Aug 2026 04:44:10 GMTWhy CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline Updates - And What's Next - simplywall.st
Tue, 04 Aug 2026 15:51:47 GMTCrispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating - TipRanks
Fri, 31 Jul 2026 01:05:02 GMTWorld's First Gene Therapy for 2-Year-Old Children | Root-Cause Intervention for Early Childhood Hematological Diseases - 36Kr
Thu, 30 Jul 2026 21:58:00 GMTMorgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? - The Globe and Mail

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for After Casgevy Expansion.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.